Fracture risk assessment three months after initiation of glucocorticoid therapy useful, recommends study
A recent study revealed the necessity of fracture risk assessment three months after the initiation of glucocorticoid (GC) therapy. The research by determined whether exposure to GCs within the first 90 days is linked to an increased risk of subsequent hip and clinical vertebral fractures.
The study utilized nationwide health insurance claims database (NDBJ) from Japan and analyzed data from patients who were over 50 years and were prescribed GCs, specifically the patients who were receiving at least 70 mg of prednisolone (PSL) or its equivalent within the initial 90 days of therapy. This study followed these patients for an additional 1080 days to monitor incidences of hip and clinical vertebral fractures. The study population included a total of 316,396 women and 299,871 men in the GC-exposed group when compared with the 43,164 women and 33,702 men in the reference group.
The key findings of this study were;
The analysis revealed a significant, dose-dependent increase in fracture risk associated with higher GC doses and longer durations within the initial 90 days of therapy.
The patients who were prescribed GCs for 30 to 59 days at doses of 5 mg PSL/day or higher had a notably increased fracture risk when compared to the reference group.
The female patients on GCs at daily doses between 1 mg and 2.5 mg PSL for the entire 90 days showed a significantly elevated fracture risk.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.